Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura

Blood (2019) 134 (Supplement_1): 1066.

https://doi.org/10.1182/blood-2019-131064

Published: 2019

Journal Articles

Association of Plasmic Score with Neurological Symptoms in Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Jose Thiago de Souza Castro, Letícia Rittner, Simone Appenzeller, Gabriela G Yamaguti-Hayakawa, MD, Marina Colella, Erich V De Paula, MD PhD, Joyce Maria Annichino- Bizzacchi, MD PhD, Fabiano Reis, Fernanda Andrade Orsi, MD

Blood (2019) 134 (Supplement_1): 4894.

https://doi.org/10.1182/blood-2019-129144

Published: 2019

Journal Articles

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Blood (2019) 134 (Supplement_1): 1082.

https://doi.org/10.1182/blood-2019-122665

Published: 2019

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Blood (2016) 128 (22): 1147.

https://doi.org/10.1182/blood.V128.22.1147.1147

Published: 2016

Journal Articles

Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

Alfred L. Garfall, MD, Eric Lancaster, MD PhD, Edward A Stadtmauer, MD, Simon F. Lacey, PhD, Karen Dengel, BSN, RN, David E Ambrose, BS, Fang Chen, PhD, Minnal Gupta, MSc, Irina Kulikovskaya, PhD, Dan T. Vogl, MD, Gabriela Plesa, PhD, Brendan M Weiss, MD, Regina Ferthio, Celeste Richardson, PhD, Jan Joseph Melenhorst, PhD, Bruce L Levine, PhD, Carl H June, MD, Michael Milone, MD PhD, Adam D. Cohen, MD

Blood (2016) 128 (22): 5702.

https://doi.org/10.1182/blood.V128.22.5702.5702

Published: 2016

Journal Articles

Zbtb11, an Evolutionarily Conserved Pu.1-Regulated Transcriptional Repressor of TP53, Is Required for Neutrophil Development

M Cristina Keightley, PhD, Duncan P. Carradice, MBBS, FRCPA, FRACP, Joly Kwek, PhD, Ashley Buckle, PhD, Judith E Layton, PhD, Joan K Heath, D.Phil, Graham J Lieschke, PhD MBBS, BMedSc, FRACP

Blood (2015) 126 (23): 1180.

https://doi.org/10.1182/blood.V126.23.1180.1180

Published: 2015

Journal Articles

Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL

Kevin J. Curran, MD, Isabelle Riviere, PhD, Rachel Kobos, MD, Nancy A. Kernan, MD, Farid Boulad, MD, Susan E. Prockop, MD, Andromachi Scaradavou, MD, Thomas M. Renaud, MD, Neerav Shukla, MD, Peter G Steinherz, MD, Jae H Park, MD, Craig S. Sauter, MD, Richard J O'Reilly, MD, Michel Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2014) 124 (21): 3716.

https://doi.org/10.1182/blood.V124.21.3716.3716

Published: 2014

Journal Articles

Detectable Or Normal ADAMTS13 Activity In Patients Presenting With Thrombotic Thrombocytopenic Purpura (TTP) Is Associated With Poor Renal Outcomes

Shruti Chaturvedi, MD, Keith R. McCrae, MD, Desiree Carcioppolo, MS

Blood (2013) 122 (21): 4752.

https://doi.org/10.1182/blood.V122.21.4752.4752

Published: 2013

Journal Articles

Thrombotic Thrombocytopenic Purpura At the Cleveland Clinic 2000–2012: Review of 100 Cases and Identification of Prognostic Factors

Shruti Chaturvedi, MD, Desiree Carcioppolo, MS, Li Zhang, PhD, Keith R. McCrae, MD

Blood (2012) 120 (21): 3325.

https://doi.org/10.1182/blood.V120.21.3325.3325

Published: 2012

Journal Articles

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Ygal Benhamou, Cyrielle Assie, Pierre-Yves Boelle, Marc Buffer, Rana Grillberger, PharmD, Sandrine Malot, Dominique Bordessoule, Lionel Galicier, MD, Elie Azoulay, MD, PhD, Hanspeter Rottensteiner, PhD, Agnes Veyradier, Paul Coppo

Blood (2011) 118 (21): 2229.

https://doi.org/10.1182/blood.V118.21.2229.2229

Published: 2011

Journal Articles

ADAMTS13 Gene Deletion Aggravates Ischemic Brain Damage

Kenji Nishio, Masayuki Fujioka, Kazuhide Hayakawa, Kenichi Mishima, Michihiro Fujiwara, Fumiaki Banno, Koichi Kokame, Toshiyuki Miyata, Yasuaki Shida, Mitsuhiko Sugimoto, Hidetada Fukushima, Kazuo Okuchi

Blood (2008) 112 (11): 260.

https://doi.org/10.1182/blood.V112.11.260.260

Published: 2008

Journal Articles

Therapeutic Plasma Exchange (TPE, plasmapheresis) for Treatment of Refractory Autoimmune Hemolytic Anemia (AIHA)

Vijay Sandilya, M.D., Lingyi Chen, MD, Rachna Anand, M.D., Eugene Choi, MD, PhD, Akhil Chopra, MD, Michael Styler, MD, Pamela Crilley, DO, David Topolsky, MD, Kristine Ward, MD

Blood (2008) 112 (11): 5380.

https://doi.org/10.1182/blood.V112.11.5380.5380

Published: 2008

Journal Articles

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignancies

Susan P. Perrine, Olivier Hermine, Trudy Small, Felipe Suarez, Richard O'Reilly, Farid Boulad, Joyce Fingeroth, Melissa Askin, Arthur Levy, Steven J. Mentzer, Massimo Di Nicola, Alessandro M. Gianni, Christoph Klein, Steven Horwitz, Douglas V. Faller

Blood (2006) 109 (6): 2571–2578.

https://doi.org/10.1182/blood-2006-01-024703

Published: 2006

Journal Articles

Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).

Daniel J. DeAngelo, MD, PhD, Philip C. Amrein, MD, Tibor J. Kovacsovics, MD, Rebecca B. Klisovic, Bayard L. Powell, MD, Michael Cooper, MD, Iain J. Webb, Richard M. Stone, MD

Blood (2006) 108 (11): 158.

https://doi.org/10.1182/blood.V108.11.158.158

Published: 2006

Journal Articles

A Phase I/II Study of Arginine Butyrate and Ganciclovir in Patients with Epstein-Barr Virus-Associated Lymphoid Malignancies.

Susan P. Perrine, MD, Olivier Hermine, MD, Steven J. Mentzer, MD, Trudy N. Small, MD, Steven M. Horwitz, MD, Joyce Fingeroth, MD, Farid Boulad, MD, Massima Di Nicola, MD, Christoph Klein, MD, PhD, Richard O’Reilly, MD, Arthur Levy, MD, Douglas V. Faller, MD, PhD.

Blood (2004) 104 (11): 609.

https://doi.org/10.1182/blood.V104.11.609.609

Published: 2004

NARROW

African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura

Association of Plasmic Score with Neurological Symptoms in Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

Zbtb11, an Evolutionarily Conserved Pu.1-Regulated Transcriptional Repressor of TP53, Is Required for Neutrophil Development

Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL

Detectable Or Normal ADAMTS13 Activity In Patients Presenting With Thrombotic Thrombocytopenic Purpura (TTP) Is Associated With Poor Renal Outcomes

Thrombotic Thrombocytopenic Purpura At the Cleveland Clinic 2000–2012: Review of 100 Cases and Identification of Prognostic Factors

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

ADAMTS13 Gene Deletion Aggravates Ischemic Brain Damage

Therapeutic Plasma Exchange (TPE, plasmapheresis) for Treatment of Refractory Autoimmune Hemolytic Anemia (AIHA)

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignancies

Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).

A Phase I/II Study of Arginine Butyrate and Ganciclovir in Patients with Epstein-Barr Virus-Associated Lymphoid Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only